They found that ALDH3A2 and GPX4 act in parallel: in AML, simultaneous inhibition of ALDH3A2 and GPX4 activity has a far greater cell-killing effect than inhibition of GPX4 activity alone. This evidence concerns the gene ALDH3A2 and acute myeloid leukemia.